Submit Deal

Robert M. Davis

Chairman and CEO at MERCK & CO

Manager

Deal Bio

Total Deals15

Valued Deals11

Total Value£34,038M

Avg. Deal Size£3,094M

Market Context

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

Expertise (15)

Key Relationships

Sort

United States

Semiconductors

PublicAcquisitionMergerMajorityCross Border

target

Versum Materials

bidder

Merck Kgaa

£4,984m

94 dealmakers

United States

Biotechnology

AcquisitionPrivate

target

Tilos Therapeutics

bidder

Merck & Co

£606m

4 dealmakers

United StatesUnited States

Pharmaceuticals

MajoritySpin OffPrivateDomesticPrivate Equity

target

Merck & Co (women’s Health, Trusted Legacy Brands, And Biosimilars Businesses)

bidder

Institutional Investors

£5,390m

17 dealmakers

United States

Health Care Services

MajorityAcquisitionPrivate

target

Staywell Company

bidder

Webmd Health Corp

value n/a

5 dealmakers

Austria

Biotechnology

AcquisitionPrivateMajorityCross BorderDisposalVenture CapitalPrivate Equity

target

Themis Bioscience

bidder

Merck & Co

value n/a

37 dealmakers

United States

Biotechnology

Venture CapitalAcquisitionDomesticPrivateMajorityPrivate Equity

target

Velosbio

bidder

Merck & Co

£2,116m

55 dealmakers

United States

Biotechnology

AcquisitionPrivateDomesticMajorityPrivate Equity

target

ONCOIMMUNE

bidder

Merck & Co

£319m

10 dealmakers

United States

Biotechnology

DomesticMinorityPrivateAcquisition

target

Seagen

bidder

Merck & Co

£767m

6 dealmakers

United States

Biotechnology

AcquisitionPublicDomesticMajorityTender Offer

target

Pandion Therapeutics

bidder

Merck & Co

£1,308m

28 dealmakers

United States

Biotechnology

DomesticMajorityAcquisitionPublic

target

Acceleron Pharma

bidder

Merck & Co

£8,528m

80 dealmakers

Switzerland

Biotechnology

AcquisitionCross BorderMajorityPrivatePrivate Equity

target

Chord Therapeutics

bidder

Merck & Co

value n/a

5 dealmakers

United States

Biotechnology

AcquisitionMinorityPrivate EquityDomesticVenture CapitalPrivate

target

Orna Therapeutics

bidder

Mpm Capital

£182m

3 dealmakers

United States

Pharmaceuticals

DomesticPublicMajorityAcquisitionTender Offer

target

Imago Biosciences

bidder

Merck & Co

£1,135m

42 dealmakers

United States

Biotechnology

DomesticAcquisitionMajorityPublic

target

Prometheus Biosciences

bidder

Merck & Co

£8,698m

50 dealmakers

United States

Biotechnology

AcquisitionDomesticPrivateMajority

target

Abceutics

bidder

Merck & Co

value n/a

1 dealmaker